Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Pharmacopeia Ramps Up Drug Quality, Safety Cooperation Across Asia With Four New Agreements With China, ASEAN States

This article was originally published in PharmAsia News

Executive Summary

BEIJING - In moves that could ultimately help elevate safety and quality standards for drugs produced across Asia, including those exported to North America, the United States Pharmacopeial Convention has signed a series of agreements with China and the Association of Southeast Asian Nations on closer scientific exchanges and joint testing of pharmaceuticals
Advertisement

Related Content

USP Looks To Maximize Opportunity As China Builds Drug Standards
USP Looks To Maximize Opportunity As China Builds Drug Standards
After Signing Pact With Chinese Regulators, U.S. Pharmacopeia Seeks To Develop New Tests To Help Prevent Deadly Episodes of Adulteration
After Signing Pact With Chinese Regulators, U.S. Pharmacopeia Seeks To Develop New Tests To Help Prevent Deadly Episodes of Adulteration
U.S. FDA, Industry Aim to Further Strengthen Pharma Supply Chain Quality
U.S. Pharmacopeial Convention Signs Pact With Chinese Regulators To Strengthen Cooperation
USP Launches Tests On Traditional Chinese Medicine Ingredients
U.S. Pharmacopeia Verifies Quality Of First Traditional Chinese Medicine Ingredient Under Voluntary Program
One Year After Spike In American Deaths From China-sourced Contaminated Heparin, U.S. Pharmocopeia Issues Revised Standards
Heparin harmonization on the horizon?
Advertisement
UsernamePublicRestriction

Register

SC072029

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel